RAYSUT-CEMENT-COMPANY
In a significant endorsement that will support exports to European Union (EU) markets, Oman’s largest cement manufacturer, Raysut Cement Company (RCC), has received CE and NF certifications, two stringent global quality norms validating RCC’s adherence to EU standards in cement production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210517005501/en/
The Muscat Stock Market (MSM)-listed RCC said the certifications come at a time when it is expanding exports to newer global markets. Currently, 50 per cent of the company’s output is exported to East Africa, India, Maldives, South Africa, and Indian Ocean islands.
“We consider CE and NF certifications a testimony to our commitment to constantly improve product quality and processes in line with rigorous global safety, quality and environmental regulations,” said Group CEO, Joey Ghose.
The CE (Conformité Européenne) mark, formerly EC mark, is mandatory for selling certain products in the European Economic Area (EEA) since 1985. The NF Mark from AFNOR certification entity is a French compliance norm that ensures product safety, quality, usage ability and performance.
“The certifications fit into our export strategy for newer geographies as the CE Mark that endorses compliance with EU’s health, safety and green regulations allows us to market our products in Iceland, Liechtenstein and Norway,” said Mr. Ghose.
Winning the certifications also coincided with RCC clinching a new export order from the Reunion Islands in the western Indian Ocean, and an annual contract has already been signed with Enterprise Audemard Group of the French island to ship 8,000 MT cement every month. The first shipment has been received by the party. RCC is also looking at setting up a grinding unit in Madagascar to leverage the 7-8 per cent Y-o-Y growth in that country’s market.
RCC has a current output of 6 million metric tonnes of cement, slated to increase to 10 million by 2022, and later to 22 million tonnes. Mr. Ghose said the COVID-19 pandemic has thrown a major challenge to the business, but RCC was facing it successfully with no change in leadership or vision.
Recently, RCC had won certifications from other parts of the world, boosting its export scope. These are from BIS (Bureau of Indian Standards), enabling it to stabilize its presence in India, and from SABPS (South African All Brothers Products and Systems) to help RCC leverage the South African market.
Mr. Salim bin Ahmed bin Alawi Al Ibrahim, Acting Deputy Group CEO of RCC said: “The cement now produced at RCC’s Salalah plant has accomplished the strictest environmental criterion of Hexavalent Chromium (Cr6+) content of less than two parts per million. The NF certification also opens up new market opportunities and we are now introducing a superior quality cement brand to the French colonies in the Indian Ocean Reunion Islands.”
Last year RCC won the ‘CEO of the Year’ honour for its Group CEO Mr. Joey Ghose, at both the Oman Best Employer Awards and GCC Best Employer Awards from Employer Branding Institute, which reinforced the company’s excellence across leadership, health and safety, technology, training and talent management.
“We regularly train our employees through on-the-job and by sending them overseas to upgrade their skills. This training helps us strictly implement quality, environmental and safety norms at our production facilities to improve our products in line with global demand,” added Mr. Al Ibrahim.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005501/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom